Moderna's COVID-19 Booster Ok'd In Europe For Immunocompromised

by Vandana Singh, Benzinga Editor

October 5, 2021 3:40 PM | 1 min read |

The European Medicines Agency (EMA) has authorized a third dose of Moderna Inc's MRNA COVID-19 vaccine for immunocompromised people.
Related Link: After Pfizer, Now Moderna Touts Data Supporting COVID-19 Booster Dose.
The approval comes for the booster given at least 28 days after the second dose to severely immunocompromised individuals 12 years of age or older.
Related: Moderna Shares Linger At 2-Month Lows: What's Next For The COVID-19 Vaccine Company.
Price Action: MRNA stock is up 2.07% at $332.49 during the market session on the last check Tuesday.
Image by Spencer Davis from Pixabay

Posted In:

Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.